OP16
Anti-c-ErbB2/c-Neu (Ab-4) Mouse mAb (7.16.4)
liquid, clone 7.16.4, Calbiochem®
Sinónimos:
Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
Productos recomendados
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
7.16.4, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
rat, human
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... ERBB2(2064)
General description
Anti-c-ErbB2/c-Neu (Ab-4), mouse monoclonal, clone 7.16.4, recognizes ~185 kDa c-ErbB2 in overexpressing B104-1-1 cells. It is validated for WB, IP, ICC, frozen sections, & growth inhibition assay.
Purified mouse monoclonal antibody generated by immunizing C3H mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in overexpressing B104-1-1 cells.
Immunogen
B104-1-1 cells overexpressing rat c-ErbB2/c-Neu
Epitope: Within the extracellular domain
Human
Application
Frozen Sections (5 g/ml, see application references)
Immunoblotting (see application references)
Immunocytochemistry (5 g/ml)
Immunoprecipitation (1 g/ml, see application references)
Neutralization Studies (not recommended, see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Analysis Note
Negative Control
Fisher rat embryo cells
Fisher rat embryo cells
Positive Control
B104-1-1 cells
B104-1-1 cells
Other Notes
Stains frozen tissue sections of rat cells overexpressing c-neu. Does not inhibit in vitro protein-tyrosine kinase activity, but it will inhibit in vivo growth of tumors overexpressing the neu oncogene (see application references). Does not cross-react with the EGF receptor. Antibody should be titrated for optimal results in individual systems.
Zhang, H., et al. 1999. Exp. Mol. Pathol.67, 15.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
10 - Combustible liquids
wgk_germany
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Rebecca A Rozich et al.
Experimental and molecular pathology, 89(3), 248-259 (2010-07-27)
Cholangiocarcinoma, a severe form of biliary cancer, has a high mortality rate resulting partially from the advanced stage of disease at earliest diagnosis. A better understanding of the progressive molecular and cellular changes occurring during spontaneous cholangiocarcinogenesis is needed to
Michela Lizier et al.
Oncotarget, 7(38), 60793-60806 (2016-08-27)
Cell fusion between neoplastic and normal cells has been suggested to play a role in the acquisition of a malignant phenotype. Several studies have pointed to the macrophage as the normal partner in this fusion, suggesting that the fused cells
Heather Gibson et al.
Oncoimmunology, 4(1), e984523-e984523 (2015-05-08)
The goal is to elucidate the immune modulating activity of an adenovirus (Adv) vector which showed therapeutic activity in human clinical trials. The oncolytic adenovirus (Adv/CD-TK) expressing two suicide genes was tested in two HER2/neu positive BALB/c mouse mammary tumor
Shannon O'Connor et al.
Protein expression and purification, 67(1), 41-47 (2009-04-21)
Receptor tyrosine kinases (RTKs) are the second largest family of membrane receptors and play a key role in the regulation of vital cellular processes, such as control of cell growth, differentiation, metabolism, and migration. The production of whole-length RTKs in
Kristina W Thiel et al.
Nucleic acids research, 40(13), 6319-6337 (2012-04-03)
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico